Literature DB >> 17057166

Is intravitreal bevacizumab (Avastin) safe?

S Michels.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17057166      PMCID： PMC1857500          DOI： 10.1136/bjo.2006.102293

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  17 in total

1.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; Andrew A Moshfeghi; Carmen A Puliafito
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2005 Jul-Aug

2.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.

Authors:  Philip J Rosenfeld; Anne E Fung; Carmen A Puliafito
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2005 Jul-Aug

3.  Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

Authors:  Jonathan Shahar; Robert L Avery; Gad Heilweil; Adiel Barak; Esther Zemel; Geoffrey P Lewis; Patrick T Johnson; Steven K Fisher; Ido Perlman; Anat Loewenstein
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

Review 4.  The safety of bevacizumab.

Authors:  Rachel E Sanborn; Alan B Sandler
Journal:  Expert Opin Drug Saf       Date:  2006-03       Impact factor: 4.250

5.  Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment.

Authors:  Raj K Maturi; Laura A Bleau; Donald L Wilson
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

6.  Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.

Authors:  Diana Iturralde; Richard F Spaide; Catherine B Meyerle; Jay M Klancnik; Lawrence A Yannuzzi; Yale L Fisher; John Sorenson; Jason S Slakter; K Bailey Freund; Michael Cooney; Howard F Fine
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

7.  Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.

Authors:  Richard F Spaide; Yale L Fisher
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

8.  Testing intravitreal toxicity of bevacizumab (Avastin).

Authors:  Roberta P A Manzano; Gholam A Peyman; Palwasha Khan; Muhamet Kivilcim
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

9.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.

Authors:  Stephan Michels; Philip J Rosenfeld; Carmen A Puliafito; Erin N Marcus; Anna S Venkatraman
Journal:  Ophthalmology       Date:  2005-06       Impact factor: 12.079

10.  The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.

Authors:  A E Fung; P J Rosenfeld; E Reichel
Journal:  Br J Ophthalmol       Date:  2006-07-19       Impact factor: 4.638
View more
  10 in total

1.  [Age-related macular degeneration and risk of stroke].

Authors:  V Biousse; M-G Bousser; A Gaudric
Journal:  J Fr Ophtalmol       Date:  2008-01       Impact factor: 0.818

Review 2.  Intravitreal anti-VEGF agents and cardiovascular risk.

Authors:  Massimo Porta; Elio Striglia
Journal:  Intern Emerg Med       Date:  2019-12-17       Impact factor: 3.397

3.  Hydrophilic Lens Opacification after Intravitreal Anti-VEGF Injections: A Case Series.

Authors:  Charbel Wahab; Jad Ayash; Kevin Sayegh; Fady Sammouh; Elias L Warrak
Journal:  Case Rep Ophthalmol       Date:  2022-03-17

4.  Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections.

Authors:  Andreas Stahl; Nicolas Feltgen; Antje Fuchs; Michael Bach
Journal:  Doc Ophthalmol       Date:  2008-06-20       Impact factor: 2.379

Review 5.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

6.  Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients.

Authors:  Focke Ziemssen; Matthias Lüke; Andre Messias; Julia Beutel; Olcay Tatar; Eberhart Zrenner; Karl U Bartz-Schmidt
Journal:  Int Ophthalmol       Date:  2007-07-20       Impact factor: 2.031

7.  Treatment of age-related macular degeneration: focus on ranibizumab.

Authors:  Martin S Spitzer; Focke Ziemssen; Karl U Bartz-Schmidt; Faik Gelisken; Peter Szurman
Journal:  Clin Ophthalmol       Date:  2008-03

8.  Plasma-activated medium suppresses choroidal neovascularization in mice: a new therapeutic concept for age-related macular degeneration.

Authors:  Fuxiang Ye; Hiroki Kaneko; Yosuke Nagasaka; Ryo Ijima; Kae Nakamura; Masatoshi Nagaya; Kei Takayama; Hiroaki Kajiyama; Takeshi Senga; Hiromasa Tanaka; Masaaki Mizuno; Fumitaka Kikkawa; Masaru Hori; Hiroko Terasaki
Journal:  Sci Rep       Date:  2015-01-09       Impact factor: 4.379

9.  An in vitro study on the effect of bevacizumab on endothelial cell proliferation and VEGF concentration level in patients with hereditary hemorrhagic telangiectasia.

Authors:  Haneen Sadick; Elena Schäfer; Christel Weiss; Nicole Rotter; Cornelia Emika Müller; Richard Birk; Maliha Sadick; Daniel Häussler
Journal:  Exp Ther Med       Date:  2022-07-05       Impact factor: 2.751

Review 10.  A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.

Authors:  Christine Schmucker; Christoph Ehlken; Hansjuergen T Agostini; Gerd Antes; Gerta Ruecker; Monika Lelgemann; Yoon K Loke
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.